EVLO OTC
Evelo Biosciences, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -80.0%
1Y: -80.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$101M
-4.7% ▼
Capital Expenditures
$622K
+59.1% ▲
5Y CAGR: -18.6%
Free Cash Flow
-$102M
-3.7% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$21M
-3001.5% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$57M | -$85M | -$94M | -$122M | -$115M |
| Depreciation & Amort. | $2M | $2M | $2M | $2M | $2M |
| Stock-Based Comp. | $6M | $8M | $8M | $16M | $15M |
| Change in Working Capital | $1M | $3M | $8M | $2M | -$10M |
| Other Non-Cash Items | $103K | $255K | $2M | $2M | $6M |
| Operating Cash Flow | -$47M | -$72M | -$73M | -$97M | -$101M |
| — Investing Activities — | |||||
| Capital Expenditures | -$5M | -$3M | -$1M | -$2M | -$622K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | -$136M | $0 | $0 | $0 | $0 |
| Investment Sales | $81M | $55M | $0 | $0 | $0 |
| Other Investing | $171K | $2K | $6K | $38K | $0 |
| Investing Cash Flow | -$60M | $52M | -$1M | -$1M | -$622K |
| — Financing Activities — | |||||
| Net Debt Issuance | $5M | $4M | $10M | $15M | -$3M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$128K | $511K | $471K | $1M | $234K |
| Financing Cash Flow | $162M | $5M | $65M | $98M | $82M |
| Net Change in Cash | $55M | -$15M | -$9M | -$666K | -$21M |
| Cash End of Period | $94M | $79M | $70M | $70M | $49M |
| Free Cash Flow | -$53M | -$75M | -$74M | -$98M | -$102M |